Alpha 2.0
Login Register
» Articles » PMID: 96736

Unpredictable Response of Pseudomonas Aeruginosa to Synergistic Antibiotic Combinations in Vitro

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1978 May 1
PMID 96736
Citations 10
Authors
H S HEINEMAN
W M Lofton
Affiliations
Soon will be listed here.
Abstract

The combined activity of ticarcillin and each of three aminoglycosides, gentamicin, tobramycin, and amikacin, was studied with 45 clinical isolates of Pseudomonas aeruginosa. All strains individually were susceptible to each of these agents. Comparison of the results revealed highly variable interaction, both from strain to strain and from one aminoglycoside to another against the same strain. Against 11 strains, none of three antibiotic pairs tested was synergistic by conventional criteria; against the remaining 34, three, any two, or any one pair among those tested was synergistic. The minimal inhibitory concentrations of individual drugs gave no indication of the degree of synergism to be expected. We conclude that generalizations about the behavior of this organism vis-à-vis penicillin-aminoglycoside combinations in vitro are subject to many exceptions. Furthermore, no test using a particular antibiotic combination is reliable as a screen for other combinations. If this experience is duplicated in vivo, combination testing may be as important for the choice of combination therapy as individual susceptibility testing is for the choice of individual antibiotics.

Citing Articles

Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that model responses.

Davis K, Morales Y, Ende R, Peters R, McCabe A, Mecsas J mBio. 2024; 15(3):e0015924.

PMID: 38364199 PMC: 10936441. DOI: 10.1128/mbio.00159-24.

Combination therapy for treatment of infections with gram-negative bacteria.

Tamma P, Cosgrove S, Maragakis L Clin Microbiol Rev. 2012; 25(3):450-70.

PMID: 22763634 PMC: 3416487. DOI: 10.1128/CMR.05041-11.

Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S Eur J Clin Microbiol Infect Dis. 2006; 25(1):25-30.

PMID: 16402226 DOI: 10.1007/s10096-005-0076-9.

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Tessier F, Quentin C Eur J Clin Microbiol Infect Dis. 1997; 16(2):159-62.

PMID: 9105845 DOI: 10.1007/BF01709477.

Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Brogden R, Heel R, Speight T, Avery G Drugs. 1980; 20(5):325-52.

PMID: 7002527 DOI: 10.2165/00003495-198020050-00001.

References
1.
Comber K, Basker M, Osborne C, Sutherland R . Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother. 1977; 11(6):956-64. PMC: 352110. DOI: 10.1128/AAC.11.6.956. View
2.
Parsley T, Provonchee R, Glicksman C, Zinner S . Synergistic activity of trimethoprim and amikacin against gram-negative bacilli. Antimicrob Agents Chemother. 1977; 12(3):349-52. PMC: 429917. DOI: 10.1128/AAC.12.3.349. View
3.
Kluge R, Standiford H, Tatem B, YOUNG V, Greene W, Schimpff S . Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1974; 6(4):442-6. PMC: 444668. DOI: 10.1128/AAC.6.4.442. View
4.
Brumfitt W, Percival A, Leigh D . Clinical and laboratory studies with carbenicillin. A new penicillin active against Pseudomonas pyocyanea. Lancet. 1967; 1(7503):1289-93. DOI: 10.1016/s0140-6736(67)91590-5. View
5.
Klastersky J, Henri A, Vandenborre L . Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin. Am J Med Sci. 1973; 266(1):13-21. DOI: 10.1097/00000441-197307000-00002. View